Results 261 to 270 of about 48,370 (295)

DDAVP Induces Systemic Release of Urokinase-Type Plasminogen Activator

Thrombosis and Haemostasis, 1989
SummaryThe desamino-d-arginine vasopressin (DDAVP) induced enhancement of endogenous fibrinolysis is generally attributed to the release of tissue-type plasminogen activator (t-PA) from the vessel wall.The observation of concurrent release of urokinase-type plasminogen activator (u-PA), which eventually might cooperate in the enhanced fibrinolytic ...
Levi M, ten Cate JW, Dooijewaard G, Sturk A, Brommer EJ, AGNELLI, Giancarlo   +5 more
openaire   +5 more sources

Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation

Thrombosis Research, 2002
The amino terminal fragment (ATF, Ser(1)-Lys(135)) of urokinase-type plasminogen activator (uPA) containing an epidermal growth factor-like (EGF) and kringle domain is critically involved in some important functions of uPA, such as receptor binding and chemotactic activity.
Ziyong, Sun, Pei-Xiang, Zhang, Ping, Wang, Victor, Gurewich, Hai-Yan, Shen, Jian-Ning, Liu   +5 more
openaire   +2 more sources

Predictive Impact of Urokinase-Type Plasminogen Activator

Cancer Research, 2004
Abstract One of the most thoroughly studied systems in relation to its prognostic relevance in patients with breast cancer, is the plasminogen activation system. This system comprises of, among others, the urokinase-type plasminogen activator (uPA) and its main inhibitor (PAI-1).
Peggy Manders, Vivianne C. G. Tjan-Heijnen, Paul N. Span, Nicolai Grebenchtchikov, John A. Foekens, Louk V. A. M. Beex, C. G. J. (Fred) Sweep   +6 more
openaire   +1 more source

Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator

Current Pharmaceutical Design, 2003
Urokinase type plasminogen activator (uPA) activates plasminogen to plasmin and is often associated with diseases where tissue remodeling is essential (e.g. cancer, macular degeneration, atherosclerosis). We discuss some of the mechanisms of uPA action in diseases, and evidence that some of the early uPA inhibitors can modulate the progression of these
Todd W, Rockway, Vincent L, Giranda
openaire   +2 more sources

Prostate‐specific antigen activates single‐chain urokinase‐type plasminogen activator

International Journal of Cancer, 1995
AbstractProstate‐specific antigen (PSA) increases in the plasma of patients with prostate cancer, and has therefore been used as a reliable tumor marker. It has been demonstrated that prostate cancer cells over‐express urokinase‐type plasminogen activator (uPA), which plays an important role in tumor invasion and metastasis.
E, Yoshida, S, Ohmura, M, Sugiki, M, Maruyama, H, Mihara   +4 more
openaire   +2 more sources

Urokinase-type plasminogen activator receptor

AfCS-Nature Molecule Pages, 2009
Nicolai Sidenius, Francesco Blasi
openaire   +1 more source

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Nature Medicine, 2021
Evdoxia Kyriazopoulou, Haralampos Milionis, Konstantinos Tsiakos   +2 more
exaly  

Urokinase-Type Plasminogen Activator and PAI-1

2006
Urokinase plasminogen activator (uPA) is a serine protease causally involved in tumor progression. In vivo, uPA can be inhibited by the serpin inhibitor plasminogen activator inhibitor-1 (PAI-1). However, PAI-1 is a multifunctional protein that can also play a role in cell migration, cell adhesion, angiogenesis, and apoptosis.
openaire   +1 more source

Urokinase-Type Plasminogen Activator

2008
openaire   +2 more sources

Xanthomonas diversity, virulence and plant–pathogen interactions

Nature Reviews Microbiology, 2020
Sujan Timilsina, Neha Potnis, Prabha Liyanapathiranage   +2 more
exaly